Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.
Daily albumin infusion to achieve serum albumin levels of ≥30 g/L did not reduce the risk of infection, renal dysfunction, or mortality in individuals with acute decompensated cirrhosis, according to results of the ATTIRE* study presented at ILC 2020.
Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.
In virologically suppressed patients with chronic hepatitis B virus (HBV) infection, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not affect their rates of viral suppression, according to the final 96-week analysis of a phase III study.
The combination therapy of cilofexor (CILO) and firsocostat (FIR) missed the primary endpoint but achieved improvements in other secondary parameters including fibrosis markers, disease activity, and liver function in patients with fibrosis due to NASH*, according to the ATLAS trial presented at digital ILC 2020.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
A trivalent vaccine against hepatitis (hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver-related deaths and is associated with a variety of malignancies, according to a new study presented at the Digital International Liver Congress (ILC) 2020.
Faecal microbiota transplantation (FMT) may be a viable treatment option for patients with severe alcoholic hepatitis (SAH), reports a study presented at the Digital International Liver Congress (ILC) 2020.
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.